Incyte Corp.

Incyte Corporation is an American multinational biopharmaceutical company with its headquarters in Wilmington, Delaware. The company was founded in 1991 and is primarily focused on the discovery, development and marketing of therapeutics for use in patients with serious unmet medical needs. The firm employs around 1,500 people worldwide, with facilities in the US, Canada, Europe and Japan. The company operates in two main therapeutic areas. It has a focus on Haematology and Oncology, which is comprised of Myeloproliferative Neoplasms (MPNs) and Graft-Versus-Host Disease (GVHD) research, as well as addressing solid tumours and hematologic malignancies. The other therapeutic area of focus is Inflammation and Autoimmunity (IAI), which includes the firm’s dermatology commercial franchise. The company’s main products in the area of oncology are Jakafi, Pemazyre and MONJUVI. In the area of dermatology, the firm produces Opzelura, a novel, prescription, inhibitor cream used for the treatment of chronic eczema. The company offers resources and support for patients via its website, including medical information, education and awareness materials. Incyte Corporation is listed on the NASDAQ where it trades under the stock ticker INCY. You can easily monitor the INCY price chart for value changes by adding this stock to your eToro virtual portfolio today.